▶ Fluvoxamine moderately to markedly increases the exposure

to aminophylline. Avoid.rStudy

▶ Fluvoxamine decreases the clearance of anaesthetics, local

(ropivacaine). Avoid prolonged use.oStudy

▶ Fluvoxamine is predicted to increase the exposure to

anagrelide.oTheoretical → Also see TABLE 4 p. 1375

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to dapoxetine. Adjust dapoxetine dose with moderate

inhibitors of CYP3A4, p. 821.oTheoretical

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to SSRIs (citalopram, escitalopram, fluoxetine,

fluvoxamine, paroxetine, sertraline).rTheoretical → Also see

TABLE 9 p. 1377

▶ Fluvoxamine is predicted to increase the exposure to

antiarrhythmics

o

(propafenone). Monitor and adjust dose.

Study

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to anticholinesterases, centrally acting (galantamine).

Monitor and adjust dose.oStudy

▶ Antiepileptics (fosphenytoin, phenytoin) decrease the

concentration of paroxetine.oStudy

▶ Sertraline potentially increases the risk of toxicity when given

with antiepileptics (fosphenytoin, phenytoin). Monitor

concentration and adjust dose.rAnecdotal

▶ SSRIs (fluoxetine, fluvoxamine) are predicted to increase the

concentration of antiepileptics (fosphenytoin, phenytoin).

Monitor and adjust dose.rAnecdotal

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to dapoxetine. Adjust

dapoxetine

o

dose with moderate inhibitors of CYP3A4, p. 821.

Theoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to moderately increase the exposure to dapoxetine.

Avoid potent inhibitors of CYP3A4 or adjust dapoxetine dose,

p. 821.rStudy

▶ Antifungals, azoles (voriconazole) are predicted to increase the

exposure to citalopram.rTheoretical → Also see TABLE 9

p. 1377

▶ Antihistamines, sedating (cyproheptadine) potentially decrease

the effects of SSRIs.oAnecdotal

▶ Apalutamide is predicted to decrease the exposure to

citalopram. Avoid or monitor.nStudy → Also see TABLE 9

p. 1377

▶ Aprepitant is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to moderately

increase the exposure to aripiprazole. Adjust aripiprazole dose,

p. 395.oStudy

▶ Fluvoxamine

Study

increases the exposure to asenapine.o ▶ Paroxetine

o

moderately increases the exposure to asenapine.

Study

▶ SSRIs (fluoxetine, paroxetine) are predicted to markedly

increase the exposure to

Study

atomoxetine. Adjust dose.r

1530 Sodium stibogluconate — SSRIs BNF 78

Interactions | Appendix 1

A1

▶ Fluvoxamine moderately increases the concentration of beta

blockers, non-selective (propranolol).oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to

o

beta blockers, selective (metoprolol, nebivolol).

Study

▶ Bupropion

o

is predicted to increase the exposure to dapoxetine.

Theoretical → Also see TABLE 13 p. 1378

▶ Fluvoxamine markedly decreases the clearance of caffeine

citrate. Monitor and adjust dose.rStudy

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to dapoxetine. Adjust dapoxetine dose

with moderate inhibitors of CYP3A4, p. 821.oTheoretical

▶ SSRIs (fluoxetine, fluvoxamine) are predicted to increase the

exposure to

Theoretical →

cilostazol

Also see TABLE 4

. Adjust

p. 1375

cilostazol dose, p. 232.o ▶ Cinacalcet

o

is predicted to increase the exposure to dapoxetine.

Theoretical

▶ Fluvoxamine is predicted to increase the exposure to

cinacalcet. Adjust dose.oTheoretical

▶ SSRIs (fluoxetine, fluvoxamine) potentially increase the

exposure to clobazam. Adjust dose.oTheoretical

▶ SSRIs (fluoxetine, fluvoxamine) are predicted to decrease the

efficacy of clopidogrel. Avoid.rTheoretical → Also see

TABLE 4 p. 1375

▶ Fluvoxamine increases the concentration of clozapine. Monitor

side effects and adjust dose.rStudy

▶ Cobicistat is predicted to moderately increase the exposure to

dapoxetine. Avoid potent inhibitors of CYP3A4 or adjust

dapoxetine dose, p. 821.rStudy

▶ Crizotinib is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to slightly increase

the exposure to darifenacin.nStudy

▶ Fluvoxamine

o

moderately increases the exposure to diazepam.

Study

▶ Fluvoxamine is predicted to increase the exposure to dopamine

receptor agonists (ropinirole). Adjust dose.oStudy

▶ Fluvoxamine markedly increases the exposure to duloxetine.

Avoid.rStudy → Also see TABLE 18 p. 1379 → Also see TABLE 13

p. 1378 → Also see TABLE 4 p. 1375

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to eliglustat. Avoid or adjust dose—consult product

literature.rStudy

▶ Fluvoxamine is predicted to increase the exposure to

eltrombopag.oTheoretical

▶ Fluvoxamine is predicted to increase the exposure to erlotinib.

Monitor side effects and adjust dose.oTheoretical

▶ Fluvoxamine

r

increases the concentration of frovatriptan.

Study → Also see TABLE 13 p. 1378

▶ Grapefruit juice moderately increases the exposure to

sertraline. Avoid.oStudy

▶ H2 receptor antagonists (cimetidine) slightly increase the

exposure to

o SSRIs (citalopram, escitalopram). Adjust dose.

Study

▶ H2 receptor antagonists (cimetidine) slightly increase the

exposure to SSRIs (paroxetine, sertraline).oStudy

▶ Fluoxetine increases the concentration of haloperidol. Adjust

dose.oAnecdotal

▶ Fluvoxamine increases the concentration of haloperidol.

Adjust dose.oStudy

▶ HIV-protease inhibitors are predicted to moderately increase

the exposure to dapoxetine. Avoid potent inhibitors of

CYP3A4 or adjust dapoxetine dose, p. 821.rStudy

▶ Idelalisib is predicted to moderately increase the exposure to

dapoxetine. Avoid potent inhibitors of CYP3A4 or adjust

dapoxetine dose, p. 821.rStudy

▶ Imatinib is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ Fluoxetine is predicted to increase the exposure to lomitapide.

Separate administration by 12 hours.qTheoretical

▶ Fluvoxamine is predicted to increase the exposure to

lomitapide

Theoretical

. Separate administration by 12 hours.o

▶ Fluvoxamine is predicted to increase the exposure to loxapine.

Avoid.qTheoretical

▶ Macrolides (clarithromycin) are predicted to moderately

increase the exposure to dapoxetine. Avoid potent inhibitors

of CYP3A4 or adjust dapoxetine dose, p. 821.rStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to dapoxetine. Adjust dapoxetine dose with moderate

inhibitors of CYP3A4, p. 821.oTheoretical

▶ Fluvoxamine very markedly increases the exposure to

melatonin. Avoid.rStudy

▶ SSRIs (fluoxetine, fluvoxamine, paroxetine) are predicted to

increase the exposure to mexiletine.oStudy

▶ Netupitant is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ SSRIs potentially increase the risk of prolonged

neuromuscular blockade when given with neuromuscular

blocking drugs, non-depolarising

Theoretical

(mivacurium).q ▶ Nilotinib is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ Fluvoxamine moderately increases the exposure to olanzapine.

Adjust dose.rAnecdotal

▶ SSRIs (fluoxetine, paroxetine) are predicted to decrease the

efficacy of opioids (codeine).oTheoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to decrease the

efficacy of opioids (tramadol).rStudy → Also see TABLE 13

p. 1378

▶ Fluvoxamine is predicted to increase the exposure to

pentoxifylline.oTheoretical

▶ Fluvoxamine is predicted to moderately increase the exposure

to pirfenidone. Avoid.oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to moderately

increase the exposure to pitolisant. Use with caution and

adjust dose.oStudy

▶ Fluvoxamine moderately increases the exposure to

pomalidomide. Adjust pomalidomide dose, p. 961.oStudy

▶ Paroxetine slightly increases the exposure to procyclidine.

Monitor and adjust dose.oStudy

▶ Proton pump inhibitors (esomeprazole) are predicted to slightly

to moderately increase the exposure to SSRIs (citalopram,

escitalopram). Monitor and adjust dose.rTheoretical

▶ Proton pump inhibitors (omeprazole) slightly to moderately

increase the exposure to SSRIs (citalopram, escitalopram).

Monitor and adjust dose.rStudy

▶ Fluvoxamine

o

is predicted to increase the exposure to riluzole.

Theoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to risperidone. Adjust dose.oStudy

▶ Fluvoxamine is predicted to increase the exposure to

roflumilast.oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to SSRIs (dapoxetine).oTheoretical → Also see

TABLE 18 p. 1379 → Also see TABLE 13 p. 1378 → Also see TABLE 4

p. 1375

▶ SSRIs potentially increase the risk of prolonged

neuromuscular blockade when given with

q

suxamethonium.

Theoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to decrease the

efficacy of tamoxifen. Avoid.rStudy

▶ Terbinafine is predicted to increase the exposure to fluoxetine.

Adjust dose.oTheoretical

▶ Terbinafine

o

moderately increases the exposure to paroxetine.

Study

▶ Terbinafine is predicted to increase the exposure to SSRIs

(citalopram, dapoxetine, escitalopram, fluvoxamine, sertraline)

o .

Theoretical

▶ Fluvoxamine moderately to markedly increases the exposure

to theophylline. Avoid.rStudy

▶ Fluvoxamine very markedly increases the exposure to

tizanidine. Avoid.rStudy

▶ SSRIs (fluoxetine, fluvoxamine) given with a moderate CYP3A4

inhibitor are predicted to increase the exposure to tofacitinib.

Adjust tofacitinib dose, p. 1105.oStudy

BNF 78 SSRIs — SSRIs 1531

Interactions | Appendix 1

A1

SSRIs (continued)

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to tricyclic antidepressants. Monitor for toxicity and

adjust dose.rStudy → Also see TABLE 18 p. 1379 → Also see

TABLE 13 p. 1378

▶ Fluvoxamine increases the exposure to tricyclic antidepressants

(amitriptyline, imipramine). Adjust dose.rStudy → Also see

TABLE 18 p. 1379 → Also see TABLE 13 p. 1378

▶ Fluvoxamine markedly increases the exposure to tricyclic

antidepressants (clomipramine). Adjust dose.rStudy → Also

see TABLE 18 p. 1379 → Also see TABLE 13 p. 1378

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to

Study → Also see

vortioxetine

TABLE 13 p. 1378

. Monitor and adjust dose.

→ Also see TABLE 4 p. 1375

o ▶ Fluvoxamine is predicted to increase the exposure to

zolmitriptan

Theoretical →

. Adjust

Also see TABLE 13

zolmitriptan

p. 1378

dose, p. 482.r

St John’s Wort → see TABLE 13 p. 1378 (serotonin syndrome)

▶ St John’s Wort is predicted to decrease the exposure to

abemaciclib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

afatinib.oStudy

▶ St John’s Wort is predicted to slightly decrease the exposure to

aldosterone antagonists (eplerenone). Avoid.oStudy

▶ St John

Study

’s Wort decreases the exposure to aliskiren.o ▶ St John’s Wort moderately decreases the exposure to

alprazolam.oStudy

▶ St John’s Wort is predicted to decrease the concentration of

aminophylline.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antiarrhythmics (dronedarone). Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antiepileptics (brivaracetam).oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

antiepileptics

o

(carbamazepine). Monitor and adjust dose.

Theoretical

▶ St John’s Wort is predicted to decrease the concentration of

antiepileptics (fosphenytoin, phenobarbital, phenytoin,

primidone). Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antiepileptics

Theoretical

(perampanel). Monitor and adjust dose.o ▶ St John’s Wort is predicted to decrease the exposure to

antiepileptics (tiagabine). Avoid.nTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antifungals, azoles (isavuconazole). Avoid.rTheoretical

▶ St John’s Wort moderately decreases the exposure to

antifungals, azoles (voriconazole). Avoid.oStudy

▶ St John’s Wort is predicted to decrease the concentration of

antimalarials (piperaquine). Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

apixaban. Use with caution or avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

apremilast. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

aprepitant. Avoid.oTheoretical

▶ St John

o’s Wort is predicted to decrease the exposure to axitinib.

Theoretical

▶ St John’s Wort is predicted to decrease the exposure to

bedaquiline. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

bictegravir. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

bosentan. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

bosutinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

brigatinib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

cabozantinib.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to calcium

channel blockers (amlodipine, felodipine, lacidipine,

lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and

adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to calcium

channel blockers (diltiazem, verapamil).oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

cariprazine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ceritinib. Avoid.rTheoretical

▶ St John’s Wort decreases the concentration of ciclosporin.

Avoid.oStudy

▶ St John

o’s Wort is predicted to alter the effects of cilostazol.

Theoretical

▶ St John’s Wort is predicted to decrease the exposure to

cobicistat. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

cobimetinib. Avoid.rTheoretical

▶ St John’s Wort decreases the efficacy of combined hormonal

contraceptives. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rAnecdotal

▶ St John’s Wort decreases the anticoagulant effect of coumarins.

Avoid.rAnecdotal

▶ St John’s Wort is predicted to decrease the exposure to

crizotinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

dabigatran. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

darifenacin.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

dasabuvir. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

dasatinib.rStudy

▶ St John’s Wort is predicted to decrease the efficacy of

desogestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ St John

r’s Wort decreases the concentration of digoxin. Avoid.

Anecdotal

▶ St John’s Wort decreases the exposure to dolutegravir. Adjust

dose.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

doravirine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

edoxaban.oStudy

▶ St John’s Wort is predicted to decrease the concentration of

efavirenz. Avoid.rTheoretical

▶ St John’s Wort is predicted to moderately decrease the

exposure to elbasvir. Avoid.rStudy

▶ St John’s Wort is predicted to increase the exposure to

eliglustat. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

encorafenib.rTheoretical

▶ St John’s Wort is predicted to decrease the effects of

ergotamine.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

erlotinib.rTheoretical

▶ St John’s Wort is predicted to decrease the efficacy of

etonogestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

etravirine. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

everolimus. Avoid or adjust dose.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

exemestane.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

fesoterodine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

fingolimod. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

fosaprepitant. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

gefitinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

glecaprevir. Avoid.rStudy

▶ St John’s Wort is predicted to markedly decrease the exposure

to grazoprevir. Avoid.rStudy

1532 SSRIs — St John’s Wort BNF 78

Interactions | Appendix 1

A1

▶ St John’s Wort is predicted to decrease the concentration of

guanfacine. Adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to HIVprotease inhibitors. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the efficacy of hormone

replacement therapy.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ibrutinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

idelalisib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

imatinib.oStudy

▶ St John’s Wort slightly decreases the exposure to irinotecan.

Avoid.rStudy

▶ St John

o’s Wort decreases the exposure to ivabradine. Avoid.

Study

▶ St John’s Wort is predicted to decrease the exposure to

ivacaftor.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ixazomib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

lapatinib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

ledipasvir. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

letermovir.oTheoretical

▶ St John’s Wort is predicted to decrease the efficacy of

levonorgestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

lurasidone. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

macitentan. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

maraviroc. Avoid.rTheoretical

▶ St John’s Wort moderately decreases the exposure to

midazolam. Monitor and adjust dose.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

midostaurin. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

naloxegol. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

netupitant.oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

nevirapine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

nilotinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

nintedanib.oStudy

▶ St John’s Wort is predicted to decrease the efficacy of

norethisterone. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rAnecdotal

▶ St John’s Wort is predicted to decrease the exposure to

olaparib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ombitasvir. Avoid.rTheoretical

▶ St John’s Wort decreases the exposure to opioids (methadone).

Monitor and adjust dose.rStudy → Also see TABLE 13 p. 1378

▶ St John’s Wort moderately decreases the exposure to opioids

(oxycodone). Adjust dose.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

osimertinib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ospemifene.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

palbociclib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

paliperidone.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ St John’s Wort is predicted to decrease the exposure to

phosphodiesterase type-5 inhibitors.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

pibrentasvir. Avoid.rStudy

▶ St John’s Wort slightly decreases the exposure to pioglitazone.

nStudy

▶ St John’s Wort is predicted to decrease the exposure to

pitolisant. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ponatinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

quetiapine.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

ranolazine. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

ribociclib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

rilpivirine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

rolapitant. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

ruxolitinib. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

sirolimus. Monitor and adjust dose.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

sofosbuvir. Avoid.rStudy

▶ St John’s Wort slightly decreases the exposure to statins

(atorvastatin).nStudy

▶ St John’s Wort moderately decreases the exposure to statins

(simvastatin).oStudy

▶ St John’s Wort decreases the concentration of tacrolimus.

Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to taxanes

(cabazitaxel). Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tenofovir alafenamide. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tezacaftor. Avoid.rTheoretical

▶ St John’s Wort potentially decreases the exposure to

theophylline.rAnecdotal

▶ St John’s Wort is predicted to decrease the exposure to

ticagrelor.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tivozanib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

tofacitinib.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

tolvaptan. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more